Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis

19 Mar 2024

Abstract excerpt

Optimal therapeutic approaches for advanced Langerhans cell histiocytosis (LCH) are not known. We assessed the safety and efficacy of combined chemotherapy with MAPK pathway inhibition in 10 patients with refractory systemic disease and/or LCH-associated neurodegeneration. Overall response rate was 9/10 (90%) for the entire cohort: 5/5 (100%) for patients with systemic disease and 6/7 (86%) for patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic and rare skin diseases.
Share to Genital Health and Disease
Share to Histiocytic Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38501390
DOI: 10.1111/bjh.19380

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosisPMID 38501390Read ↗

From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies.Semantic proximity Read ↗

Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.Semantic proximity Read ↗

Clinical features and treatment of Langerhans cell histiocytosis.Semantic proximity Read ↗

Langerhans cell histiocytosis.Semantic proximity Read ↗

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice.Semantic proximity Read ↗

Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy.Semantic proximity Read ↗

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.Semantic proximity Read ↗

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.Semantic proximity Read ↗

Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.Semantic proximity Read ↗

Clinical and prognostic features of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.